Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heiko Becker

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2024
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)David Witte, Ina Pretzell, Timm M Reissig, et al.
Nature Medicine|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, et al.
Nature Medicine|June 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Cell|March 10, 2010
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blastsAnna M Eiring, Jason G Harb, Paolo Neviani, et al.
Blood|November 20, 2012
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutationsSebastian Schwind, Colin G Edwards, Deedra Nicolet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B studyKlaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2024
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)David Witte, Ina Pretzell, Timm M Reissig, et al.
Nature Medicine|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, et al.
Nature Medicine|June 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Cell|March 10, 2010
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blastsAnna M Eiring, Jason G Harb, Paolo Neviani, et al.
Blood|November 20, 2012
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutationsSebastian Schwind, Colin G Edwards, Deedra Nicolet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B studyKlaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.
Pageof 10